These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31101399)

  • 1. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
    Orringer CE
    Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines.
    Orringer CE
    Methodist Debakey Cardiovasc J; 2019; 15(1):16-22. PubMed ID: 31049145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
    Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS
    Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483
    [No Abstract]   [Full Text] [Related]  

  • 6. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
    Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP;
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment in a preventive cardiology clinic utilizing advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management gaps among a primary-prevention population compared with a propensity-matched primary-care cohort: A team-based care model and its impact on lipid and blood pressure management.
    Fentanes E; Vande Hei AG; Holuby RS; Suarez N; Slim Y; Slim JN; Slim AM; Thomas D
    Clin Cardiol; 2018 Jun; 41(6):817-824. PubMed ID: 29667200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    Circulation; 2019 Jun; 139(25):e1046-e1081. PubMed ID: 30565953
    [No Abstract]   [Full Text] [Related]  

  • 11. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH; Phan YL; Spinler SA
    J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    Circulation; 2019 Jun; 139(25):e1082-e1143. PubMed ID: 30586774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
    Mason RP; Libby P; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
    Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS
    J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.